ReviewiScience2026
The emerging roles of ITM2A: At the molecular crossroads of development and pathogenesis.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Integral membrane protein 2A (ITM2A) is a type II transmembrane glycoprotein belonging to the BRICHOS superfamily. It primarily regulates organismal development and homeostasis and exhibits tumor-suppressive functions. Its expression is precisely regulated by a multidimensional network involving transcription factors, epigenetic modifications, and environmental signals. Within cellular signaling networks, ITM2A modulates multiple key pathways, including BMP, JAK/STAT, ERK, Hedgehog, and PKA-CREB. ITM2A is essential for the differentiation and functional maturation of various tissues, such as cartilage, bone, and muscle. Dysregulation of ITM2A function or expression is closely associated with malignancies, thyroid disorders, and acute transplant rejection. This review systematically summarizes the complex regulatory mechanisms of ITM2A in growth, development, and disease, with a particular focus on skeletal development and tumorigenesis, aiming to provide a theoretical basis for its potential use as a biomarker for development and disease diagnosis/treatment, as well as for the development of ITM2A-targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.